COLLABORATION AND LICENCE AGREEMENTCollaboration and Licence Agreement • April 27th, 2015 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
COLLABORATION AND LICENCE AGREEMENT DATED JANUARY 4, 2022 EXSCIENTIA AI LIMITED and SANOFI Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the...Collaboration and Licence Agreement • March 23rd, 2023 • Exscientia PLC • Biological products, (no disgnostic substances) • New York
Schedule Page 1. Target Selection Process 78 2. Subcontractors 79 3. Target Prioritisation Criteria 80 4. Validation Criteria 81 5. Form of Material Transfer Agreement 82 6. Development Candidate Data Package Requirements 87 7. Initial Pathways of Interest 88 8. Intentionally Left Blank 89 9. Intentionally Left Blank 90 10. Research Plan for [***] 91 11. Research Plan For [***] 92 12. Form of Translational Research Plan 93
COLLABORATION AND LICENCE AGREEMENTCollaboration and Licence Agreement • November 14th, 2006 • Acologix, Inc. • Pharmaceutical preparations • London
UNIVERSITY COLLEGE LONDON, incorporated in the United Kingdom by Royal Charter, acting through its Royal Free and University College Medical School and Freemedic plc, whose address is Rowland Hill Street, London NW3 2PF, United Kingdom (together, “RFUCMS”)
ContractCollaboration and Licence Agreement • April 4th, 2024 • Pharming Group N.V. • Pharmaceutical preparations
and-Collaboration and Licence Agreement • July 20th, 2000 • Gemini Genomics PLC • Services-commercial physical & biological research • New South Wales
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[*]”. COLLABORATION AND...Collaboration and Licence Agreement • February 14th, 2024 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This Collaboration and Licence Agreement (the “Agreement”) is made and entered into the 10th day of May, 2002 (the “Effective Date”) by and between:
COLLABORATION AND LICENCE AGREEMENT1 by and between ASTRAZENECA UK LIMITED and CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED and CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC DATE: 21 NOVEMBER 2004Collaboration and Licence Agreement • December 16th, 2004 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • England and Wales
NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:
COLLABORATION AND LICENCE AGREEMENT DATED 15 AUGUST 2005 AMONG UCB S.A. AND IMCLONE SYSTEMS INCORPORATEDCollaboration and Licence Agreement • November 8th, 2005 • Imclone Systems Inc/De • Biological products, (no disgnostic substances) • New York
NOW THEREFORE, in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, UCB and ImClone, intending to be legally bound, do hereby agree as follows:
ContractCollaboration and Licence Agreement • August 3rd, 2023 • BICYCLE THERAPEUTICS PLC • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
COLLABORATION AND LICENCE AGREEMENTCollaboration and Licence Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This Collaboration and Licence Agreement (this “Agreement”) is made effective as of 11th of April 2019 (the “Effective Date”), by and between
